Europe Nuclear Medicine Market – Trends And Forecasts (2016 - 2021)

  • ID: 2967296
  • Report
  • Region: Europe
  • 105 pages
  • Mordor Intelligence
1 of 4
Europe's Nuclear Medicine Market Expected To Reach $1.9 Billion In 2019


  • Covidien
  • IBA Group
  • Lantheus Medical Imaging
  • NTP Radioisotopes
  • Triad Isotopes
  • MORE
Europe market for nuclear medicine stood at $1.4 billion in 2014 and is expected to reach approximately $1.9 billion in 2019 with a CAGR of 7.2%. Market for Technetium-99m is expected to increase owing to the rise in cases of cancer and cardiac ailments.

Nuclear medicine has high potential for treatment of neurological diseases like Parkinson’s, Alzheimer’s and dementia. Practitioners prefer radiopharmaceuticals over conventional methods of treatments in neurological diseases.

Study estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030.

Radiopharmaceutical market is driven by increasing use of SPECT and PET therapy, increasing awareness of people for radiopharmaceuticals, ready availability of nuclear isotopes. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy. Another driving factor for the market is the umbrella organisation for Nuclear Medicine, EANM in Europe which stands ready for political follow up and professional input to guarantee patient care and patient safety throughout Europe. Further upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the nuclear reactor , NRU in 2016 and OSIRIS in 2018 , is a major threat for the radiopharmaceutical market.

The market is segmented by applications (Diagnostic and Therapeutic). Diagnostic market consists of SPECT and PET radioisotopes. The therapeutic market is segmented as Beta emitters, Alpha emitters and brachytherapy. Countries covered include Germany, France, UK , Spain and Italy.

Short half life of the radioisotopes , high capital investment involved and more regulatory guidelines are the major constraints for the market.

Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are 5 major nuclear reactors in the world and rest of the countries are dependent on them for supply of radiopharmaceuticals.

Major players in the market are Covidien , IBA Group, Lantheus Medical Imaging, Triad Isotopes, Siemens Healthcare (PETNET Solutions), NTP Radioisotopes.

What makes our report unique?

1) For gaining an exhaustive understanding of the Europe nuclear medicine market.
2) Would be of assistance in providing a comprehensive analysis of the major trends and associated prospects for market growth over the coming half a decade.
3.An ideal opportunity for industry consultants, other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
4) Wide-ranging information provided about the leading market players and the major strategies adopted by them.
Note: Product cover images may vary from those shown
2 of 4


  • Covidien
  • IBA Group
  • Lantheus Medical Imaging
  • NTP Radioisotopes
  • Triad Isotopes
  • MORE
1.1 Nuclear medicine procedures
1.2 Major nuclear medicine products
1.3 The S-Curve of nuclear medicine
1.4 Market Matrix


3.1 Definition of radiopharmaceuticals

4. Market Dynamics
4.1 Market Drivers
4.1.1 Increasing incidents of Cancer and Cardiac ailments
4.1.2 Increasing use of SPECT and PET analysis in radiopharmaceuticals
4.1.3 Increasing awareness of radiopharmaceuticals
4.1.4 Public Awareness
4.1.5 Ready availability of radiopharmaceuticals
4.2 Market Constraints
4.2.1 Shorter half life of radiopharmaceuticals
4.2.2 High capiltal investment
4.2.3 Regulatory Guidelines
4.2.4 Reimbursement issues
4.3 Opportunities
4.3.1 Potential radioisotopes in pipeline
4.3.2 Increasing neurological applications
4.3.3 Cyclotron based production
4.4 Threat
4.4.1 Shutdown of Nuclear reactors

5. Europe Nuclear Medicine Market Segmentation
5.1 Nuclear Medicine Market, By Type of Products
5.1.1 Diagnostic Market SPECT Radioisotopes Technetium-99m (TC-99m) Thallium-201 (TL-201) Iodine (I-123) Gallium -67( Ga-67) PET Radioisotopes Fluorine-18 Rubidium-82 (RB-82) Others
5.1.2 Therapeutic Market Beta Emitters Alpha Emitters Brachytherapy
5.2 Europe Nuclear medicine Diagnostics market, By applications
5.2.1 SPECT Cardiology Lymphoma Thyroid Neurology Others
5.2.2 PET Oncology Cardiology Neurology Others
5.3 Europe Nuclear Medicine Therapeutic Market, By Application
5.3.1 Thyroid
5.3.2 Bone Metastasis
5.3.3 Lymphoma
5.3.4 Endocrine Tumors
5.4 Europe Country wise segmentation
5.4.1 Germany
5.4.2 United Kingdom
5.4.3 France
5.4.4 Spain
5.4.5 Italy

6.1 Acquisitions and mergers
6.2 New product launch
6.3 Agreements and collaborations
6.4 Market Share Analysis
6.5 Expansions

7.1 Covidien
7.2 IBA Group
7.3 Lantheus Medical Imaging
7.4 Triad Isotopes
7.5 Siemens Healthcare (PETNET Solutions)
7.6 NTP Radioisotopes

8. Appendix
8.1 .Abbreviations
Note: Product cover images may vary from those shown
3 of 4


4 of 4
- Covidien
- IBA Group
- Lantheus Medical Imaging
- NTP Radioisotopes
- Siemens Healthcare (PETNET Solutions)
- Triad Isotopes
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown